Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prednicarbate + octenidine
- Development stage
- Phase 2
- Lead developer
- Almirall
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
LAS41003 is a topical combination drug developed by Almirall for the treatment of inflammatory skin conditions such as tinea pedis (athlete's foot), candidiasis, and atopic dermatitis. The formulation combines prednicarbate—a glucocorticoid receptor agonist corticosteroid—with octenidine, an antiseptic agent. Its mechanism of action involves anti-inflammatory effects via glucocorticoid receptor activation (prednicarbate) and antimicrobial activity (octenidine). The drug was investigated in multiple Phase 2 clinical trials for dermatological indications but has not been approved or marketed[2][4][7].
- Other names
- prednicarbate/octenidineoctenidine/prednicarbateLAS189961/LAS189962
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on prednicarbate + octenidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prednicarbate + octenidine.